Toll Free: 1-888-928-9744
Published: May, 2015 | Pages:
65 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Emergent BioSolutions Inc. - Product Pipeline Review - 2015 Summary Global Markets Direct's, 'Emergent BioSolutions Inc. - Product Pipeline Review - 2015', provides an overview of the Emergent BioSolutions Inc.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Emergent BioSolutions Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Emergent BioSolutions Inc. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Emergent BioSolutions Inc.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Emergent BioSolutions Inc.'s pipeline products Reason to Buy - Evaluate Emergent BioSolutions Inc.'s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Emergent BioSolutions Inc. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Emergent BioSolutions Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Emergent BioSolutions Inc. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Emergent BioSolutions Inc. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Explore the dormant and discontinued projects of Emergent BioSolutions Inc. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 Emergent BioSolutions Inc. Snapshot 6 Emergent BioSolutions Inc. Overview 6 Key Information 6 Key Facts 6 Emergent BioSolutions Inc. - Research and Development Overview 7 Key Therapeutic Areas 7 Emergent BioSolutions Inc. - Pipeline Review 10 Pipeline Products by Stage of Development 10 Pipeline Products - Monotherapy 11 Pipeline Products - Partnered Products 12 Partnered Products/Combination Treatment Modalities 13 Emergent BioSolutions Inc. - Pipeline Products Glance 14 Emergent BioSolutions Inc. - Late Stage Pipeline Products 14 Filing rejected/Withdrawn Products/Combination Treatment Modalities 14 Emergent BioSolutions Inc. - Clinical Stage Pipeline Products 15 Phase II Products/Combination Treatment Modalities 15 Phase I Products/Combination Treatment Modalities 16 Emergent BioSolutions Inc. - Early Stage Pipeline Products 17 Preclinical Products/Combination Treatment Modalities 17 Discovery Products/Combination Treatment Modalities 18 Emergent BioSolutions Inc. - Drug Profiles 19 coagulation factor IX (recombinant) 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 AV-7909 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 otlertuzumab 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 PreviThrax 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 AVP-21D9 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 ES-414 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 antihemophilic factor (recombinant) 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 ES-210 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 ES-301 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 ES-306 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 EV-035 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 GC-072 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 Monoclonal Antibody to Inhibit Hemagglutinin for Influenza 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 MVA-RSV 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 MVAH-5HA 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 Recombinant Protein Cytotoxic to Cells Expressing CD19 and CD3 for Cancer 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 Recombinant Protein to Target HER-2 and CD3 for Cancer 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 Recombinant Protein to Target RON and CD3 for Cancer 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 Vaccines for Undisclosed Indication 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 Emergent BioSolutions Inc. - Pipeline Analysis 42 Emergent BioSolutions Inc. - Pipeline Products by Target 42 Emergent BioSolutions Inc. - Pipeline Products by Route of Administration 44 Emergent BioSolutions Inc. - Pipeline Products by Molecule Type 45 Emergent BioSolutions Inc. - Pipeline Products by Mechanism of Action 46 Emergent BioSolutions Inc. - Recent Pipeline Updates 48 Emergent BioSolutions Inc. - Dormant Projects 56 Emergent BioSolutions Inc. - Discontinued Pipeline Products 57 Discontinued Pipeline Product Profiles 57 Anthrivig 57 Immune Globulin 57 Leucotropin 57 PEP-35 57 TST-10088 57 Emergent BioSolutions Inc. - Company Statement 58 Emergent BioSolutions Inc. - Locations And Subsidiaries 61 Head Office 61 Other Locations & Subsidiaries 61 Appendix 64 Methodology 64 Coverage 64 Secondary Research 64 Primary Research 64 Expert Panel Validation 64 Contact Us 64 Disclaimer 65
List of Tables
Emergent BioSolutions Inc., Key Information 6 Emergent BioSolutions Inc., Key Facts 6 Emergent BioSolutions Inc. - Pipeline by Indication, 2015 8 Emergent BioSolutions Inc. - Pipeline by Stage of Development, 2015 10 Emergent BioSolutions Inc. - Monotherapy Products in Pipeline, 2015 11 Emergent BioSolutions Inc. - Partnered Products in Pipeline, 2015 12 Emergent BioSolutions Inc. - Partnered Products/ Combination Treatment Modalities, 2015 13 Emergent BioSolutions Inc. - Filing rejected/Withdrawn, 2015 14 Emergent BioSolutions Inc. - Phase II, 2015 15 Emergent BioSolutions Inc. - Phase I, 2015 16 Emergent BioSolutions Inc. - Preclinical, 2015 17 Emergent BioSolutions Inc. - Discovery, 2015 18 Emergent BioSolutions Inc. - Pipeline by Target, 2015 43 Emergent BioSolutions Inc. - Pipeline by Route of Administration, 2015 44 Emergent BioSolutions Inc. - Pipeline by Molecule Type, 2015 45 Emergent BioSolutions Inc. - Pipeline Products by Mechanism of Action, 2015 47 Emergent BioSolutions Inc. - Recent Pipeline Updates, 2015 48 Emergent BioSolutions Inc. - Dormant Developmental Projects,2015 56 Emergent BioSolutions Inc. - Discontinued Pipeline Products, 2015 57 Emergent BioSolutions Inc., Other Locations 61 Emergent BioSolutions Inc., Subsidiaries 61
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.